Available Data

The database contains a subset of the trial data and includes baseline characteristics and 10 year followup information on all 1,829 patients. Endpoints include subsequent revascularization, new myocardial infarction or death.

Objectives

The BARI (Bypass Angioplasty Revascularization Investigation) trial was designed to compare survival in patients randomized to receive either percutaneous transluminal coronary balloon angioplasty (PTCA) or coronary artery bypass grafting (CABG).

Background

Angioplasty and bypass surgery have been compared in numerous studies, but long-term clinical outcomes are limited. Symptomatic patients with multivessel coronary artery disease (n = 1,829) were randomly assigned to initial treatment with PTCA or CABG and followed up for an average of 10.4 years.

Conclusions

There was no significant long-term disadvantage regarding mortality or myocardial infarction associated with an initial strategy of PTCA compared with CABG. Among patients with treated diabetes, CABG conferred long-term survival benefit, whereas the 2 initial strategies were equivalent regarding survival for patients without diabetes.

Request Data

Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.